Rosalind Advisors, Inc. Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001622627

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 33 positions · Total reported value $269.06M · Top-10 concentration 74.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.8% · 9 new · 11 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +4.7% · vs SPY +2.5% · Prev Value $269.06M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -5.8% · vs SPY -7.9% · Latest Value $244.66M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Rosalind Advisors, Inc. disclosed 33 equity positions with a combined reported value of $269.06M. The filing implies a focused portfolio: its ten largest positions account for 74.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were DCTH ($41.55M), FENC ($34.27M), XERS ($23.04M). By sector, the heaviest allocations are Health Care 94.7%, Industrials 5.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.0pp) and away from Other (-0.8pp).

Versus the prior quarter, Rosalind Advisors, Inc. opened 9 new positions, trimmed 11 and fully exited 3, a turnover rate of 54.8% of positions. The portfolio's overlap with the prior quarter was 66% of names.

The largest new positions opened in Q2 2026 were ABVX ($2.78M), SLS ($2.30M), SPRB ($1.08M).

Of the 3 positions fully exited versus the prior quarter, the largest were REPL ($2.75M), DFTX ($2.36M), LPCN ($1.77M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ABVX ABIVAX SA · $2.78M
  • SLS SELLAS LIFE SCIENCES GROUP I · $2.30M
  • SPRB SPRUCE BIOSCIENCES INC · $1.08M
  • PEPG PEPGEN INC · $630.00K
  • ELDN ELEDON PHARMACEUTICALS INC · $130.78K
  • TENX TENAX THERAPEUTICS INC · $13.95K

Fully Exited (vs previous quarter)

  • REPL REPLIMUNE GROUP INC · prev qtr: $2.75M · history
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $2.36M
  • LPCN LIPOCINE INC NEW · prev qtr: $1.77M
  • AVTX AVALO THERAPEUTICS INC · prev qtr: $1.12M
  • ANNX ANNEXON INC · prev qtr: $1.11M
  • QQQ INVESCO QQQ TR · prev qtr: $1.05M · history
  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $958.50K
  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $52.72K

Insider Transactions (Form 4)

Latest Rosalind Advisors, Inc. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-10-13 J DELCATH SYSTEMS, INC. 27,502 — SEC filing
2026-10-13 Conversion DELCATH SYSTEMS, INC. 3,627 — SEC filing

All insider transactions →

Fund Profile

Rosalind Advisors, Inc. is an SEC-registered 13F filer. As of Q2 2026 it reported 33 US equity positions with a combined value of $269.06M. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Portfolio Structure

  • 33 positions · $269.06M reported value (Q2 2026)
  • Top 10 holdings = 74.1% of reported value
  • Largest position: DCTH (DELCATH SYS INC) at 15.4%
  • Average position size: $8.15M

Sector Tilt

  • Health Care 94.7%
  • Industrials 5.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 7 added, 12 reduced, 8 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund's actions this quarter suggest a cautious approach with a focus on health care, indicating a belief in the sector's potential. The addition of new positions and the reduction in others without a significant shift in total holdings indicates a preference for maintaining a balanced portfolio. 2. Key Moves: - Added: FENC (Fenec Pharmaceuticals), VSTM (Verastem Inc), HELP (Cybin Inc), reflecting a push into biopharmaceuticals and potentially emerging markets within health care. - Reduced: XERS (Xeris Biopharma Holdings), SVRA (Savara Inc), VOR (VOR Biopharma Inc), PCVX (Vaxcyte Inc), which indicates a reevaluation and possibly a reduction in exposure to certain health care companies. - Hold: DCTH (Delcath Systems), FENC (Fenec Pharmaceuticals), XFOR (X4 Pharmaceuticals), EYPT (EyePoint Inc), suggesting a commitment to existing positions or sectors. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be moderately active, with a mix of holds, adds, and reduces but no dramatic shifts in strategy. - Sector Bias: The fund has a clear bias towards the health care sector, with a total of 8 out of 10 holdings in health care. - Risk Appetite: The addition of high-growth companies like VSTM and HELP suggests a willingness to take on higher risk for potential high returns. 4. Per-Holding One-Liner: - DCTH: Specializes in medical devices for liver cancer treatment; 'unverified' - FENC: Biopharmaceutical company focusing on drug development for cancer; 'unverified' - XERS: Biopharmaceutical company focusing on diabetes and endocrine disorders; 'unverified' - SVRA: Biopharmaceutical company focusing on treatments for respiratory and orphan diseases; 'unverified' - VSTM: Biopharmaceutical company focused on cancer and immunology; 'unverified' - XFOR: Biopharmaceutical company focusing on treatments for cancer and ophthalmology; 'unverified' - EYPT: Ophthalmology company focusing on drug delivery systems for eye diseases; 'unverified' - HELP: Biopharmaceutical company focusing on psychedelic-based treatments for mental health; 'unverified' - VOR: Biopharmaceutical company focused on treatments for cancer and inflammation; 'unverified' - PCVX: Biopharmaceutical company focusing on cell therapies for cancer and rare diseases; 'unverified' 5. One-Sentence Style Summary: Rosalind Advisors maintained a health care-centric portfolio in Q2 2026, selectively adding growth-oriented positions while trimming others, reflecting a cautious yet proactive strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 94.7%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 3.30M $41.55M 15.44%
15.44%
Hold
2 3.19M $34.27M 12.74%
12.74%
Add
3 2.91M $23.04M 8.56%
8.56%
Reduce
4 3.18M $19.58M 7.28%
7.28%
Reduce
5 3.99M $15.23M 5.66%
5.66%
Add
6 3.21M $15.01M 5.58%
5.58%
Hold
7 988.23K $14.13M 5.25%
5.25%
Reduce
8 1.96M $12.93M 4.81%
4.81%
Add
9 648.60K $11.94M 4.44%
4.44%
Reduce
10 200.00K $11.63M 4.32%
4.32%
Reduce
11 749.05K $11.01M 4.09%
4.09%
Hold
12 200.00K $7.44M 2.77%
2.77%
Reduce
13 721.50K $7.22M 2.68%
2.68%
Reduce
14 828.12K $5.51M 2.05%
2.05%
Hold
15 5.17M $5.32M 1.98%
1.98%
Add
16 1.07M $4.98M 1.85%
1.85%
Reduce
17 3.64M $3.78M 1.41%
1.41%
Reduce
18 1.11M $2.98M 1.11%
1.11%
Hold
19 508.06K $2.97M 1.10%
1.10%
Add
20 20.87K $2.78M 1.03%
1.03%
New
21 3.91M $2.73M 1.02%
1.02%
Hold
22 701.68K $2.48M 0.92%
0.92%
Add
23 568.70K $2.30M 0.86%
0.86%
New
24 389.45K $1.98M 0.73%
0.73%
Reduce
25 1.28M $1.21M 0.45%
0.45%
Add
26 100.00K $1.10M 0.41%
0.41%
Hold
27 20.00K $1.08M 0.40%
0.40%
New
28 250.00K $1.04M 0.39%
0.39%
Hold
29 150.00K $684.00K 0.25%
0.25%
Reduce
30 350.00K $630.00K 0.23%
0.23%
New
31 31.00K $375.10K 0.14%
0.14%
Reduce
32 50.30K $130.78K 0.05%
0.05%
New
33 6.20K $13.95K 0.01%
0.01%
New

FAQ

What did Rosalind Advisors, Inc. buy in 2026-Q2?

In its 2026-Q2 13F filing, Rosalind Advisors, Inc. reported 33 equity positions worth $269.06M in aggregate; its largest disclosed positions were DCTH ($41.55M), FENC ($34.27M), XERS ($23.04M).

How large is Rosalind Advisors, Inc.'s portfolio?

Rosalind Advisors, Inc. reported $269.06M of long equity holdings across 33 positions as of 2026-Q2. Top-10 holdings account for 74.1% of reported value.

What is Rosalind Advisors, Inc.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/rosalind-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →